Circio Holding Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
CRNA
- Investments
-
1
- Share Price
-
$0.97
- (As of Thursday Closing)
Circio Holding General Information
Description
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.
Contact Information
Website
www.circio.comCorporate Office
- Tordenskiolds Gate 2
- 0160 Oslo
- Norway
Corporate Office
- Tordenskiolds Gate 2
- 0160 Oslo
- Norway
Circio Holding Timeline
Circio Holding Stock Performance
As of 12-Nov-2026, Circio Holding’s stock price is $0.97. Its current market cap is $283M with 291M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.97 | $0.98 | $0.09 - $1.68 | $283M | 291M | 7.01M | -$0.04 |
Circio Holding Financials Summary
As of 30-Jun-2026, Circio Holding has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 203,896 | 17,118 | 6,104 | 11,821 |
| Revenue | 0 | 0 | 0 | 12 |
| EBITDA | (6,883) | (4,400) | 5,334 | (10,221) |
| Net Income | (6,571) | (4,412) | 5,336 | (10,662) |
| Total Assets | 54,933 | 1,070 | 1,925 | 2,528 |
| Total Debt | 0 | 832 | 1,531 | 10,858 |
Circio Holding Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Circio Holding Comparisons
Industry
Financing
Details
Circio Holding Competitors (55)
One of Circio Holding’s 55 competitors is CRISPR Therapeutics, a Formerly VC-backed company based in Zug, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| Xenetic Biosciences | Corporation | Framingham, MA |
Circio Holding Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Circio Holding Patents
Circio Holding Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020258007-A1 | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada | Inactive | 17-Apr-2019 | ||
| EP-3725323-A1 | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada | Inactive | 17-Apr-2019 | ||
| EP-3955944-A1 | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada | Inactive | 17-Apr-2019 | ||
| US-20220152134-A1 | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada | Inactive | 17-Apr-2019 | ||
| WO-2020212503-A1 | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada | Inactive | 17-Apr-2019 | C12N15/86 |
Circio Holding Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Circio Holding Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Circio Holding Acquisitions (1)
Circio Holding’s most recent deal was a Merger/Acquisition with Oncos Therapeutics for . The deal was made on 02-Jul-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oncos Therapeutics | 02-Jul-2015 | Merger/Acquisition | Biotechnology |
Circio Holding ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Circio Holding Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Targovax Solutions | Oslo, Norway | 2021 |
Circio Holding FAQs
-
When was Circio Holding founded?
Circio Holding was founded in 2010.
-
Where is Circio Holding headquartered?
Circio Holding is headquartered in Oslo, Norway.
-
What is the size of Circio Holding?
Circio Holding has 12 total employees.
-
What industry is Circio Holding in?
Circio Holding’s primary industry is Biotechnology.
-
Is Circio Holding a private or public company?
Circio Holding is a Public company.
-
What is Circio Holding’s stock symbol?
The ticker symbol for Circio Holding is CRNA.
-
What is the current stock price of Circio Holding?
As of 12-Nov-2026 the stock price of Circio Holding is $0.97.
-
What is the current market cap of Circio Holding?
The current market capitalization of Circio Holding is $283M.
-
Who are Circio Holding’s competitors?
CRISPR Therapeutics, Intellia Therapeutics, Adaptimmune Therapeutics, Adimab, and Xenetic Biosciences are some of the 55 competitors of Circio Holding.
-
What is Circio Holding’s annual earnings per share (EPS)?
Circio Holding’s EPS for 12 months was -$0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
